---
layout: default
title: Fluocinonide
parent: 僅模型預測 (L5)
nav_order: 719
evidence_level: L5
indication_count: 7
---

# Fluocinonide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **7** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Fluocinonide: From Topical Corticosteroid Therapy to Alopecia Mucinosa

## One-Sentence Summary

> Fluocinonide (DrugBank DB01047) is a high-potency topical corticosteroid; detailed original indication and mechanism-of-action records are not available in this Evidence Pack.
> The TxGNN model predicts it may be effective for **Alopecia Mucinosa**,
> but currently **0 clinical trials** and **0 publications** directly support this specific prediction — it is a model-only signal (L5).

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | No licensed/approved indication data available (drug is unmarketed in Taiwan; 0 TFDA licenses on record) |
| Predicted New Indication | Alopecia Mucinosa |
| TxGNN Prediction Score | 99.61% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for fluocinonide is not available in this Evidence Pack. Based on known pharmacological classification, fluocinonide belongs to the topical corticosteroid class, agents whose efficacy in inflammatory and pruritic dermatologic conditions is well established. Mechanistically, this class exerts anti-inflammatory and immunomodulatory effects at the site of application, which is the basis for the TxGNN prediction linking it to alopecia mucinosa.

Alopecia mucinosa (follicular mucinosis) is pathologically characterized by perifollicular lymphocytic infiltration and mucinous deposition within hair follicles. Topical corticosteroids are used in dermatology as adjunctive anti-inflammatory therapy for a range of follicular and inflammatory skin conditions, so there is a plausible mechanistic rationale for anti-inflammatory activity to be relevant here. However, this rationale is inferred from drug-class pharmacology rather than from data specific to fluocinonide in this indication.

It is worth noting that this Evidence Pack evaluated fluocinonide against several other alopecia-spectrum conditions (e.g., telogen effluvium, alopecia areata, folliculitis decalvans), all clustered at similarly high TxGNN scores. Among these, **alopecia areata** (rank 3, evidence level L3) is the only related indication with any actual supporting data — one Phase 4 trial (low relevance) and one case report — suggesting the model may be picking up a broader "topical corticosteroid ↔ hair-loss disorder" signal rather than indication-specific evidence for alopecia mucinosa itself. This convergence adds some plausibility to the general direction but does not substitute for direct evidence on alopecia mucinosa.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: TFDA label warnings/contraindications and drug interaction data are recorded as data gaps in this Evidence Pack — see Conclusion below.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction for alopecia mucinosa is supported only by a TxGNN model score (L5, S0) with no clinical trials or literature specific to this drug-disease pair, and the drug carries a **Blocking** data gap on TFDA label warnings/contraindications, which precludes even a preliminary safety assessment (S1).

**To proceed, the following is needed:**
- TFDA package insert / label data (warnings, contraindications) — currently a Blocking data gap (DG001)
- Confirmed mechanism of action from DrugBank — currently a High-severity data gap (DG002)
- Confirmation of original approved indication(s), since no TFDA license records exist for this drug in Taiwan
- Targeted literature/trial search specifically for fluocinonide (or class-effect data from other high-potency topical corticosteroids such as clobetasol or fluocinolone) in alopecia mucinosa or related follicular inflammatory disorders
- If pursuing the broader "corticosteroid for alopecia-spectrum disease" hypothesis, prioritize alopecia areata (rank 3) for follow-up, as it is the only candidate in this bundle with any existing clinical evidence
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

